Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertensionheart failure and percutenous coronary interventions (PCI).

Boston Scientific Acquires Securus Medical Group Inc.
News | Ablation Systems | April 04, 2018

April 4, 2018 — Boston Scientific Corp. announced the acquisition of Securus Medical Group Inc., a privately-held...

FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018

April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen...

American College of Cardiology, #ACC18

Most of the big stories March 2018 were the late-breaking trial presentations at the American College of Cardiology (ACC) meeting during the month.

Feature | April 02, 2018 | Dave Fornell

Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC)...

FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018

April 2, 2018 — Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval...

Videos | Cath Lab | March 27, 2018

Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional...

Videos | Intravascular Imaging | March 27, 2018

A discussion with Ron Waksman, M.D., associate director of the division of cardiology and director of cardiovascular...

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell

There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American...

Videos | Cardiac Diagnostics | March 26, 2018

James Januzzi, M.D., Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine, and director of the...

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018

March 21, 2018 — Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (...

American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018

March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help...

Videos | ACC | March 21, 2018

DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at the 2018...

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a...

Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the...

Edwards Lifesciences received European CE mark clearance for its self-expanding Centera transcatheter aortic valve replacement (TAVR) device for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.

Edwards Lifesciences received European CE mark clearance for its self-expanding Centera transcatheter aortic valve replacement (TAVR) device for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. This was the top structural heart story of the month of February 2018.

Feature | March 20, 2018 | Dave Fornell

Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC)...

Trial Bolsters Evidence in Favor of Closing Hole in Heart After Stroke
News | ACC | March 20, 2018

March 20, 2018 — Among people with a type of hole in the heart, known as patent foramen ovale (PFO), those who...

Overlay Init